Table 1.
Patient characteristics
| Number of patients (%)a | ||
|---|---|---|
| Age | Median (years) (range) | 63 (25–73) |
| Performance status | 0 | 46 (88) |
| 1 | 5 (10) | |
| 2 | 1 (2) | |
| FIGO stage | IB2 | 3 (6) |
| IIA2 | 2 (4) | |
| IIB | 16 (30) | |
| IIIA | 1 (2) | |
| IIIB | 27 (52) | |
| IVA | 3 (6) | |
| Hydronephrosis | Yes | 6 (11) |
| No | 46 (89) | |
| Histology | Squamous cell carcinoma | 44 (85) |
| Adenocarcinoma | 8 (15) | |
| Pretreatment Hbb | Median (mg/dl) (range) | 12.0 (6.1–13.8) |
| Pretreatment Crc | Median (mg/dl) (range) | 0.6 (0.3–1.4) |
| Maximum tumor diameter | Median (mm) (range) | 46 (30–100) |
| >40 mm | 36 (60) | |
| ≤40 mm | 16 (40) | |
| PLNd metastases (≥10 mm) | Negative | 32 (62) |
| Positive | 20 (38) | |
| Duration of follow-up (for all patients) | Median (months) (range) | 52 (4–123) |
aValues are presented as number (%) or median (range), bHb = hemoglobin, cCr = creatinine, dPLN = pelvic lymph node.